Bridgeway Capital Management’s Precision BioSciences DTIL Stock Holding History

Bridgeway Capital Management’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-61,901	Closed	-$258K	–	1249
2025 Q4	$258K	Hold	61,901	–	–	0.01%	971
2025 Q3	$342K	Hold	61,901	–	–	0.01%	892
2025 Q2	$260K	Buy	+61,901	New	+$305K	0.01%	900
2024 Q1	–	Sell	-8,180	Closed	-$89.6K	–	1327
2023 Q4	$89.6K	Hold	8,180	–	–	﹤0.01%	1256
2023 Q3	$83.8K	Hold	8,180	–	–	﹤0.01%	1252
2023 Q2	$129K	Sell	8,180 -2,500	-23%	-$57.2K	﹤0.01%	1216
2023 Q1	$241K	Buy	10,680 +1,630	+18%	+$53.7K	0.01%	1068
2022 Q4	$323K	Buy	9,050 +1,667	+23%	+$65.9K	0.01%	973
2022 Q3	$288K	Buy	+7,383	New	+$351K	0.01%	1052

Other funds holding DTIL

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bridgeway Capital Management's DTIL Position: Q1 2026 in Review

Bridgeway Capital Management sold out of Precision BioSciences (DTIL) in Q1 2026, closing a stake of 61,901 shares — an estimated $258K sold.

Bridgeway Capital Management first reported a position in DTIL in Q3 2022 and held it in 9 quarters. The position peaked at $342K in Q3 2025. 78 funds tracked by Wall St. Rank hold DTIL as of Q1 2026.

Bridgeway Capital Management reported no remaining Precision BioSciences position as of Q1 2026 after selling out during the quarter.
Bridgeway Capital Management sold 61,901 Precision BioSciences shares in Q1 2026, an estimated $258K.
Bridgeway Capital Management first reported a position in Precision BioSciences in Q3 2022 and held it in 9 quarters.
Bridgeway Capital Management's Precision BioSciences position peaked at $342K in Q3 2025.
78 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.